{"id":"oral-iron-erythropoietin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Gastrointestinal disturbance (from oral iron)"},{"rate":null,"effect":"Thrombotic events"},{"rate":null,"effect":"Pure red cell aplasia (rare, ESA-related)"}]},"_chembl":{"chemblId":"CHEMBL1200823","moleculeType":"Small molecule","molecularWeight":"398.14"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oral iron provides the essential mineral substrate required for hemoglobin and myoglobin synthesis, addressing iron deficiency. Erythropoietin is a hormone that stimulates erythropoiesis in the bone marrow, increasing red blood cell production. Together, they address both the iron substrate limitation and the erythropoietic drive needed to correct anemia, particularly in patients with chronic kidney disease or chemotherapy-induced anemia.","oneSentence":"This combination therapy replaces iron stores to support hemoglobin synthesis while erythropoietin stimulates red blood cell production to treat anemia.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:41.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia of chronic kidney disease"},{"name":"Chemotherapy-induced anemia"},{"name":"Iron deficiency anemia"}]},"trialDetails":[{"nctId":"NCT04040023","phase":"NA","title":"Patient Blood Management in Cardiac Surgery","status":"COMPLETED","sponsor":"Clinique Pasteur","startDate":"2019-09-10","conditions":"Surgical Blood Loss","enrollment":900},{"nctId":"NCT05340465","phase":"PHASE2","title":"Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants","status":"RECRUITING","sponsor":"University of Washington","startDate":"2022-11-27","conditions":"Prematurity, Iron-deficiency, Iron Deficiency Anemia","enrollment":120},{"nctId":"NCT07162090","phase":"PHASE4","title":"Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2025-09-10","conditions":"Sarcopenia, Anemia Associated With Chronic Kidney Disease (CKD), Dialysis Patients","enrollment":60},{"nctId":"NCT06903559","phase":"PHASE1, PHASE2","title":"Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2025-04-15","conditions":"Kidney Failure, Chronic, Malnutrition-Inflammation Syndrome, Anemia in End Stage Renal Disease","enrollment":46},{"nctId":"NCT06917950","phase":"PHASE1, PHASE2","title":"Roxadustat for Bone and Neuropsychiatric Aspects in Hemodialysis Patients","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2025-04-15","conditions":"Kidney Failure,Chronic, Anemia in End Stage Renal Disease, Depression Anxiety Disorder","enrollment":46},{"nctId":"NCT00236964","phase":"PHASE3","title":"Comparison of Oral Iron With IV Iron in Patients With Anemia of Chronic Renal Failure Not on Dialysis","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2001-02-23","conditions":"Anemia","enrollment":96},{"nctId":"NCT04343170","phase":"NA","title":"Effect of Ultra-short-term Treatment of Patients With Iron Deficiency or Anemia Undergoing Adolescent Scoliosis Correction","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-09-01","conditions":"Ultra-short-term, Iron Deficiency Anemia, Scoliosis Idiopathic","enrollment":44},{"nctId":"NCT05353348","phase":"NA","title":"Effect of the Combined Programme on Perioperative Anaemia（CPPA）","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-03-15","conditions":"Patient Blood Management, Cardiac Surgery, Iron Deficiency Anemia","enrollment":110},{"nctId":"NCT03231085","phase":"NA","title":"Comparison of the Rate of Preoperative Haemoglobin After Administration of Epoetin Alpha Associated With an Oral Medical Supplementation Versus Intravenous Before Surgery of Craniosynostosis at the Child","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2017-10-31","conditions":"Craniosynostosis","enrollment":100},{"nctId":"NCT02278341","phase":"PHASE3","title":"Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-11-21","conditions":"Anemia, End Stage Renal Disease (ESRD)","enrollment":838},{"nctId":"NCT02021318","phase":"PHASE3","title":"Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-03-12","conditions":"Anemia in Chronic Kidney Disease in Non-dialysis Patients","enrollment":616},{"nctId":"NCT04655027","phase":"PHASE4","title":"A Study to Investigate the Effect of Roxadustat Versus Recombinant Human Erythropoietin (rHuEPO) on Oral Iron Absorption in Chinese Patients With Anemia of Chronic Kidney Disease (CKD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-02-22","conditions":"Anemia of Chronic Kidney Disease","enrollment":25},{"nctId":"NCT03409107","phase":"PHASE3","title":"Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-05","conditions":"Anaemia","enrollment":614},{"nctId":"NCT02876835","phase":"PHASE3","title":"Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09-27","conditions":"Anaemia","enrollment":3872},{"nctId":"NCT03446612","phase":"PHASE2","title":"Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-01-10","conditions":"Anaemia","enrollment":6},{"nctId":"NCT03457701","phase":"PHASE2","title":"Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-07-30","conditions":"Anaemia","enrollment":15},{"nctId":"NCT04269707","phase":"PHASE3","title":"Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044","status":"COMPLETED","sponsor":"American Regent, Inc.","startDate":"2019-11-19","conditions":"Iron Deficiency Anemia","enrollment":7},{"nctId":"NCT01147666","phase":"PHASE2","title":"Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2010-05-17","conditions":"End Stage Renal Disease, Anemia","enrollment":161},{"nctId":"NCT02879305","phase":"PHASE3","title":"Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09-28","conditions":"Anaemia, Aspergillosis, Allergic Bronchopulmonary","enrollment":2964},{"nctId":"NCT03029208","phase":"PHASE3","title":"Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-05-11","conditions":"Anaemia","enrollment":312},{"nctId":"NCT01414075","phase":"PHASE2","title":"Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2011-07-21","conditions":"Dialysis, Anemia","enrollment":60},{"nctId":"NCT00223938","phase":"PHASE4","title":"Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.","status":"TERMINATED","sponsor":"Sanofi","startDate":"2003-12-30","conditions":"Anemia","enrollment":112},{"nctId":"NCT02189889","phase":"PHASE1, PHASE2","title":"Active Preoperative Anemia Management in Patients Undergoing Cardiac Surgery","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2013-04-09","conditions":"Anemia, Cardiovascular Disease","enrollment":5},{"nctId":"NCT04464850","phase":"PHASE3","title":"Intravenous Versus Oral Iron Therapy in Hemodialysis Patients","status":"UNKNOWN","sponsor":"Chiang Mai University","startDate":"2020-07-29","conditions":"Hemodialysis Complication, Anemia, Iron Deficiency Anemia","enrollment":124},{"nctId":"NCT02496377","phase":"NA","title":"Cross Iron (Comparative Randomized Oral Versus Systemic IRON)","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2014-08-29","conditions":"Allogenic Transfusion, Perioperative Anaemia, Knee Arthroplasty","enrollment":100},{"nctId":"NCT02412449","phase":"PHASE1","title":"Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2015-04","conditions":"Healthy","enrollment":18},{"nctId":"NCT02327546","phase":"PHASE1","title":"Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2014-12","conditions":"Healthy Volunteers","enrollment":10},{"nctId":"NCT03286712","phase":"PHASE4","title":"The Effect on Vascular Reactivity Using the Erythropoeitin Alpha on Incident Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"National Kidney and Transplant Institute, Philippines","startDate":"2015-10","conditions":"Chronic Kidney Disease, Anemia, Complication of Peritoneal Dialysis","enrollment":30},{"nctId":"NCT03010579","phase":"PHASE4","title":"Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Peking University","startDate":"2016-10","conditions":"Anemia, Lymphoma, Hematopoietic Stem Cell Transplantation","enrollment":70},{"nctId":"NCT02780505","phase":"PHASE4","title":"Assessment of the Effect of Vitamin C on Anemia in Patients With Continuous Ambulatory Peritoneal Dialysis","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2011-11","conditions":"Anemia","enrollment":66},{"nctId":"NCT00223977","phase":"PHASE2, PHASE3","title":"2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2003-12","conditions":"Iron Deficiency Anemia","enrollment":146},{"nctId":"NCT00224042","phase":"PHASE4","title":"Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2003-04","conditions":"Anemia, Iron-Deficiency, Kidney Failure, Chronic","enrollment":52},{"nctId":"NCT00224068","phase":"PHASE4","title":"Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy","status":"COMPLETED","sponsor":"Watson Pharmaceuticals","startDate":"2002-05","conditions":"Anemia","enrollment":180},{"nctId":"NCT00661999","phase":"PHASE3","title":"Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2006-01","conditions":"Anemia, Leukemia, Lymphoma","enrollment":502}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ferrous sulfate"],"phase":"phase_3","status":"active","brandName":"Oral Iron + Erythropoietin","genericName":"Oral Iron + Erythropoietin","companyName":"American Regent, Inc.","companyId":"american-regent-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy replaces iron stores to support hemoglobin synthesis while erythropoietin stimulates red blood cell production to treat anemia. Used for Anemia of chronic kidney disease, Chemotherapy-induced anemia, Iron deficiency anemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}